Elimination of the adverse effects of tacrolimus-based induction therapy by a 5-day exposure of optimal steady-state blood concentration in renal transplant patients in the early postoperative period

Transplantation Proceedings

Volumn 31, Issue 7, 1999, Pages 2761-2762

  Ishibashi, M ^a   Miyamoto, S ^a   Nojima, M ^a   Yoshimoto, T ^a   Yabumoto, H ^a   Mori, Y ^a   Shima, H ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; MIZORIBINE; TACROLIMUS;

ANTIBODY TITER; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG SAFETY; HYPERKALEMIA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TREMOR;

DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; KIDNEY TRANSPLANTATION; METHYLPREDNISOLONE; POSTOPERATIVE PERIOD; RIBONUCLEOSIDES; TACROLIMUS; TIME FACTORS;

EID: 0032696626     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(99)00557-6     Document Type: Conference Paper

References (12)

1. Buscittil R.W., Klintmalm G.B.G., Lake J.R., et al. Transplantation. 61:1996;845.
2. Gruessner R.W.G. Transplantation. 11:1997;299.
3. Pham S.M., Kormos R.L., Hattler B.G., et al. J Thorac Cardiovasc Surg. 111:1996;764.
4. Pirsch J.D., Miller J., Deierhoi M.H., et al. Transplantation. 63:1997;977.
5. Transplantation. 64:1997;436.
6. Mendez R. Transplant Proc. 30:1998;1287.
7. Ochiai T., Fukao K., Takahashi K., et al. Transplant Proc. 27:1995;829.
8. Braun F., Lorf T., Grupp C., et al. Transplant Proc. 30:1998;1221.
9. Mollison K.W., Fey T.A., Krause R.A., et al. Toxicology. 125:1998;169.
10. Keown P.A., Stiller Cr, Muinhead N., et al. Transplant Proc. 14:1984;1626.
11. J Clin Oncol. 16:1998;301.
12. Watanabe K., Yamashita Y., Shirakusa T. Med Bull Fukuoka Univ. 24:1997;139.